Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D12QYO
|
|||
| Drug Name |
JNJ-64300535
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 1 | [1] | |
| Company |
Janssen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03463369) A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.